Biotech & Health Tech
Pfizer lifts 2026 guidance as cancer, migraine sales offset Covid slide
Pfizer raised its 2026 financial guidance as strong growth in its oncology and migraine businesses helped it weather sharp sales drops in its Covid products. The company reported third-quarter sales and ...
Pfizer raised its 2026 financial guidance as strong growth in its oncology and migraine businesses helped it weather sharp sales drops in its Covid products. The company reported third-quarter sales and ...
This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗